Loading provider…
Loading provider…
Neurology Physician in Madison, WI
NPI: 1225394802Primary Practice Location
UNIVERSITY OF WI HOSPITALS & CLINICS AUTHORITY
1675 Highland Ave, Madison, WI
Primary Employer
University of Wisconsin Medical Foundation, Inc
uwhealth.org
HQ Phone
Get Ankush's Phone Numberphone_androidMobile
Get Ankush's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardWI State Medical License
TX State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 45 | 99 |
| 2 | 99205New patient office or other outpatient visit, typically 60 minutes | 23 | 23 |
| 3 | G2212Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 14 | 21 |
| 4 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 13 | 40 |
| 5 | 99214Established patient office or other outpatient visit, 30-39 minutes | 11 | 15 |
Single-agent dabrafenib for BRAFV600E-mutated histiocytosis.
Authors: Julio Hajdenberg, Tracey Liebman, Eli Diamond, Raajit Rampal, David Hyman
Publication Date: 2018-02-24
Rethinking the need for a platelet transfusion threshold of 50 × 109 /L for lumbar puncture in cancer patients.
Authors: Helen Chung, Sejal Morjaria
Publication Date: 2020-01-18
Role of Ethnicity and Geographic Location on Glioblastoma IDH1/IDH2 Mutations.
Authors: Nitin Tandon, Leomar Ballester-Fuentes, Angel Blanco, Yoshua Esquenazi Levy
Journal: World Neurosurg
Publication Date: 2021-01-28
Lead Sponsor: Imvax
Intervention / Treatment: COMBINATION_PRODUCT: Placebo, PROCEDURE: Standard of Care (SOC): Radiation Therapy, DRUG: SOC: Temozolomide, COMBINATION_PRODUCT: IGV-001 Cell Immunotherapy
Lead Sponsor: CNS Pharmaceuticals, Inc.
Collaborators: Worldwide Clinical Trials
Intervention / Treatment: DRUG: Lomustine, DRUG: Berubicin
Lead Sponsor: National Cancer Institute (NCI)
Collaborators: NRG Oncology
Intervention / Treatment: OTHER: Questionnaire Administration, BIOLOGICAL: Nivolumab, DRUG: Temozolomide, BIOLOGICAL: Ipilimumab, OTHER: Quality-of-Life Assessment, RADIATION: Radiation Therapy, PROCEDURE: Contrast-enhanced Magnetic Resonance Imaging, DEVICE: NovoTTF-100A Device